Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Mitsuro Kanda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5464-3819; OpenAlex author ID A5018268432, A5080296127, A5112739673, A5133420757. Sources: OpenAlex.

Their work

Papers
56 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
112
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 5 papers · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: 6 papers · 2021: 4 papers · 2022: 2 papers · 2023: 6 papers · 2024: 1 paper · 2025: 2 papers · 2026: 8 papers

Papers 50 of 56

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.3840↗
  2. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Last author DOI 10.1002/ijc.70801↗
  3. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  4. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  5. Circulating SDF4 as a potential diagnostic marker for early-stage pancreatic cancer Co-author DOI 10.1038/s41598-026-63925-x↗
  6. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Last author DOI 10.1245/s10434-025-18912-3↗
  7. ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. Last author DOI 10.1245/s10434-026-19112-3↗
  8. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Last author DOI 10.1245/s10434-026-19134-x↗
  9. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  10. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.17520↗
  11. Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. Co-author DOI 10.21873/anticanres.17297↗
  12. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteri… Co-author DOI 10.1002/jhbp.1373↗
  13. Targeting Pancreatic Cancer with Novel Plumbagin Derivatives: Design, Synthesis, Molecular Mechanism, In Vitro and In Vivo Evaluation. Co-author DOI 10.1021/acs.jmedchem.3c00394↗
  14. Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.04.017↗
  15. Albumin-Globulin Ratio Indicates the Survival Outcome of Pancreatic Cancer Cases Who Underwent Preoperative Treatment and Curative Surgical Resection. Co-author DOI 10.1080/01635581.2023.2191384↗
  16. High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.16491↗
  17. Mobilization of Circulating Tumor Cells after Short- and Long-Term FOLFIRINOX and GEM/nab-PTX Chemotherapy in Xenograft Mouse Models of Human Pancreatic Cancer. Co-author DOI 10.3390/cancers15225482↗
  18. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… Co-author DOI 10.1245/s10434-022-12039-5↗
  19. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15882↗
  20. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Co-author DOI 10.1097/mpa.0000000000001712↗
  21. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. Co-author DOI 10.1186/s13148-021-01165-8↗
  22. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08990-w↗
  23. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Co-author DOI 10.21873/anticanres.15189↗
  24. Clinical impact of additional therapy for residual pancreatic cancer. Co-author DOI 10.1007/s00595-019-01900-y↗
  25. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001559↗
  26. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07981-w↗
  27. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08047-7↗
  28. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14138↗
  29. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13010036↗
  30. Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. Co-author DOI 10.1016/j.ejso.2019.05.019↗
  31. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.012↗
  32. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-28253-9↗
  33. Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001105↗
  34. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1097/mpa.0000000000001110↗
  35. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Co-author DOI 10.1097/mpa.0000000000001186↗
  36. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2017.01.075↗
  37. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Co-author DOI 10.1016/j.surg.2017.04.023↗
  38. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Co-author DOI 10.1002/jso.24147↗
  39. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Co-author DOI 10.1007/s00423-016-1412-5↗
  40. Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Co-author DOI 10.1097/md.0000000000003582↗
  41. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors … Co-author DOI 10.1097/md.0000000000004282↗
  42. Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Co-author DOI 10.18632/oncotarget.9009↗
  43. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma w… Co-author DOI 10.1097/md.0000000000001647↗
  44. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000315↗
  45. Effectiveness of plasma treatment on pancreatic cancer cells. Co-author DOI 10.3892/ijo.2015.3149↗
  46. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Co-author DOI 10.1007/s00595-013-0752-9↗
  47. Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000136↗
  48. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic h… Co-author DOI 10.1245/s10434-013-3329-3↗
  49. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Co-author PMID 25436375↗
  50. Value of peritoneal cytology in potentially resectable pancreatic cancer. Co-author DOI 10.1002/bjs.9307↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masamichi Hayashi · 31 shared papers, 2011–2026 · strength 3.84
  2. Yasuhiro Kodera · 42 shared papers, 2011–2025 · strength 3.58
  3. Suguru Yamada · 33 shared papers, 2011–2022 · strength 2.32
  4. Tsutomu Fujii · 30 shared papers, 2011–2026 · strength 2.05
  5. Fuminori Sonohara · 16 shared papers, 2018–2025 · strength 1.66
  6. Norifumi Hattori · 13 shared papers, 2015–2025 · strength 1.62
  7. Nobuhiko Nakagawa · 6 shared papers, 2020–2026 · strength 1.17
  8. Tomohisa Otsu · 6 shared papers, 2022–2026 · strength 1.14
  9. Ajay Goel · 5 shared papers, 2023–2026 · strength 1.05
  10. Daniel D. Von Hoff · 5 shared papers, 2023–2026 · strength 1.05
  11. Keizo Fujita · 4 shared papers, 2024–2026 · strength 1.02
  12. Nobutake Tanaka · 7 shared papers, 2018–2023 · strength 0.93
  13. Ryo Ashida · 3 shared papers, 2026 · strength 0.84
  14. Hiroyuki Sugimoto · 17 shared papers, 2011–2017 · strength 0.76
  15. Junpei Yamaguchi · 3 shared papers, 2026 · strength 0.67
  16. Yukihiro Yokoyama · 3 shared papers, 2026 · strength 0.67
  17. Vincent M. Chung · 3 shared papers, 2026 · strength 0.66
  18. Song Cheol Kim · 3 shared papers, 2026 · strength 0.66
  19. Haruyoshi Tanaka · 3 shared papers, 2025–2026 · strength 0.65
  20. Masaya Suenaga · 10 shared papers, 2014–2021 · strength 0.64
  21. Derek Cridebring · 3 shared papers, 2025–2026 · strength 0.61
  22. Haiyong Han · 3 shared papers, 2025–2026 · strength 0.61
  23. Erkut Hasan Borazanci · 3 shared papers, 2025–2026 · strength 0.61
  24. Shinji Mii · 3 shared papers, 2022–2026 · strength 0.57
  25. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.